DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,129 filers reported holding DANAHER CORPORATION in Q1 2017. The put-call ratio across all filers is 0.41 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $2,406,000 | +6.7% | 28,126 | -2.9% | 0.02% | -5.6% |
| Q4 2016 | $2,254,000 | -11.5% | 28,956 | -10.8% | 0.02% | -14.3% |
| Q3 2016 | $2,546,000 | -14.4% | 32,466 | +10.2% | 0.02% | -22.2% |
| Q2 2016 | $2,974,000 | -0.4% | 29,451 | -6.4% | 0.03% | -6.9% |
| Q1 2016 | $2,985,000 | +6.4% | 31,474 | +4.2% | 0.03% | 0.0% |
| Q4 2015 | $2,806,000 | +2.4% | 30,213 | -6.0% | 0.03% | -3.3% |
| Q3 2015 | $2,740,000 | -5.6% | 32,153 | -5.2% | 0.03% | -6.2% |
| Q2 2015 | $2,903,000 | +83.5% | 33,921 | +82.0% | 0.03% | +77.8% |
| Q1 2015 | $1,582,000 | +17.6% | 18,633 | +18.7% | 0.02% | +5.9% |
| Q4 2014 | $1,345,000 | -1.5% | 15,692 | -12.7% | 0.02% | -10.5% |
| Q3 2014 | $1,365,000 | -8.8% | 17,968 | -5.5% | 0.02% | -9.5% |
| Q2 2014 | $1,497,000 | +12.8% | 19,013 | +7.4% | 0.02% | 0.0% |
| Q1 2014 | $1,327,000 | +0.4% | 17,696 | +3.4% | 0.02% | -4.5% |
| Q4 2013 | $1,322,000 | -7.6% | 17,121 | -17.0% | 0.02% | -18.5% |
| Q3 2013 | $1,430,000 | +80.3% | 20,627 | +64.6% | 0.03% | +58.8% |
| Q2 2013 | $793,000 | – | 12,535 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |